Learn More
CFTR in cystic fibrosis F508 ∆ Potentiator ivacaftor abrogates pharmacological correction of Editor's Summary potentiators make CFTR less stable, accelerating the removal of this channel from the cell membrane. and Veit and coauthors now show that combining the two types of drugs does not work effectively, because surface. Other drugs, called(More)
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR). Newly developed "correctors" such as lumacaftor (VX-809) that improve CFTR maturation and trafficking and "potentiators" such as ivacaftor (VX-770) that enhance channel activity may provide important advances in CF therapy. Although VX-770 has demonstrated(More)
Lung infections with Mycobacterium abscessus, a species of multidrug-resistant nontuberculous mycobacteria, are emerging as an important global threat to individuals with cystic fibrosis (CF), in whom M. abscessus accelerates inflammatory lung damage, leading to increased morbidity and mortality. Previously, M. abscessus was thought to be independently(More)
  • 1